Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 10:20am CEST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
05/18 DAIICHI SANKYO : Data on Carboxylic Ester Hydrolases Reported by Researchers at ..
05/11 NEW ANTIBIOTICS STUDY FINDINGS HAVE : biological...
05/11 DAIICHI SANKYO : Researchers at Daiichi Sankyo Report New Data on Toxicology (Co..
05/09 DAIICHI SANKYO : Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily Lixia..
05/08 DAIICHI SANKYO : Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily Lixia..
05/04 DAIICHI SANKYO : Patent Issued for Sustained-Release Solid Preparation for Oral ..
05/04 DAIICHI SANKYO : Studies from Daiichi Sankyo, Inc. Update Current Data on Inflam..
05/01 DAIICHI SANKYO : Announces the Introduction of a Restricted Share-Based Remunera..
05/01 DAIICHI SANKYO : Announces Impairment Loss Related to Kitasato Daiichi Sankyo Va..
04/28 DAIICHI SANKYO : Announces 15 Billion Yen Manufacturing Investment to Support Ac..
More news
Sector news : Pharmaceuticals - NEC
12:32p UK competition watchdog accuses Merck of obstructing biosimilars
08:35aDJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/11 Daiichi Sankyo reports FY results
05/10 Pieris Blooms With Astra Deal
05/09 Showtime For Nektar Therapeutics
02/17 ArQule's lead product candidate tivantinib flunks late-stage liver cancer stu..
02/03 FDA rejects Charleston and Daiichi's opioid candidate
Advertisement
Financials ( JPY)
Sales 2018 901 303 M
EBIT 2018 -
Net income 2018 67 386 M
Finance 2018 367 948 M
Yield 2018 2,86%
P/E ratio 2018 24,66
P/E ratio 2019 26,30
EV / Sales 2018 1,52x
EV / Sales 2019 1,64x
Capitalization 1 734 951 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 425  JPY
Spread / Average Target -0,92%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..2.28%15 628
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
More Results